Biogen Price to Sales Ratio 2010-2022 | BIIB
Historical PS ratio values for Biogen (BIIB) over the last 10 years. The current P/S ratio for Biogen as of July 01, 2022 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Biogen P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2022-07-01 |
210.63 |
|
2.90 |
| 2022-03-31 |
210.60 |
$72.62 |
2.90 |
| 2021-12-31 |
239.92 |
$73.15 |
3.28 |
| 2021-09-30 |
282.99 |
$72.56 |
3.90 |
| 2021-06-30 |
346.27 |
$75.34 |
4.60 |
| 2021-03-31 |
279.75 |
$79.73 |
3.51 |
| 2020-12-31 |
244.86 |
$82.46 |
2.97 |
| 2020-09-30 |
283.68 |
$84.37 |
3.36 |
| 2020-06-30 |
267.55 |
$82.43 |
3.25 |
| 2020-03-31 |
316.38 |
$78.55 |
4.03 |
| 2019-12-31 |
296.73 |
$75.85 |
3.91 |
| 2019-09-30 |
232.82 |
$73.43 |
3.17 |
| 2019-06-30 |
233.87 |
$70.92 |
3.30 |
| 2019-03-31 |
236.38 |
$68.12 |
3.47 |
| 2018-12-31 |
300.92 |
$65.19 |
4.62 |
| 2018-09-30 |
353.31 |
$63.54 |
5.56 |
| 2018-06-30 |
290.24 |
$61.04 |
4.75 |
| 2018-03-31 |
273.82 |
$59.35 |
4.61 |
| 2017-12-31 |
318.57 |
$57.58 |
5.53 |
| 2017-09-30 |
313.12 |
$55.18 |
5.67 |
| 2017-06-30 |
271.36 |
$54.12 |
5.01 |
| 2017-03-31 |
273.42 |
$52.81 |
5.18 |
| 2016-12-31 |
261.39 |
$52.22 |
5.01 |
| 2016-09-30 |
288.53 |
$51.38 |
5.62 |
| 2016-06-30 |
222.89 |
$49.85 |
4.47 |
| 2016-03-31 |
239.95 |
$47.65 |
5.04 |
| 2015-12-31 |
282.37 |
$46.06 |
6.13 |
| 2015-09-30 |
268.35 |
$44.92 |
5.97 |
| 2015-06-30 |
372.33 |
$43.57 |
8.55 |
| 2015-03-31 |
389.19 |
$42.78 |
9.10 |
| 2014-12-31 |
312.88 |
$40.88 |
7.65 |
| 2014-09-30 |
304.92 |
$38.00 |
8.02 |
| 2014-06-30 |
290.63 |
$35.07 |
8.29 |
| 2014-03-31 |
281.93 |
$32.09 |
8.79 |
| 2013-12-31 |
257.69 |
$29.08 |
8.86 |
| 2013-09-30 |
221.92 |
$26.74 |
8.30 |
| 2013-06-30 |
198.36 |
$24.89 |
7.97 |
| 2013-03-31 |
177.54 |
$23.58 |
7.53 |
| 2012-12-31 |
134.91 |
$22.98 |
5.87 |
| 2012-09-30 |
137.53 |
$22.48 |
6.12 |
| 2012-06-30 |
133.08 |
$22.00 |
6.05 |
| 2012-03-31 |
116.14 |
$21.03 |
5.52 |
| 2011-12-31 |
101.44 |
$20.61 |
4.92 |
| 2011-09-30 |
85.86 |
$19.98 |
4.30 |
| 2011-06-30 |
98.55 |
$19.49 |
5.06 |
| 2011-03-31 |
67.72 |
$19.19 |
3.53 |
| 2010-12-31 |
61.80 |
$18.34 |
3.37 |
| 2010-09-30 |
51.73 |
$17.45 |
2.96 |
| 2010-06-30 |
43.74 |
$16.44 |
2.66 |
| 2010-03-31 |
52.90 |
$15.58 |
3.40 |
| 2009-12-31 |
49.31 |
$15.09 |
3.27 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$30.847B |
$10.982B |
|
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
|
